Disc Medicine Inc.
$ 60.34
-1.24%
05 Mar - close price
- Market Cap 2,306,535,000 USD
- Current Price $ 60.34
- High / Low $ 61.80 / 59.76
- Stock P/E N/A
- Book Value 19.52
- EPS -5.37
- Next Earning Report 2026-05-07
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.36 %
- 52 Week High 99.50
- 52 Week Low 30.82
About
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$100.17
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-03-19 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-11 | 2023-05-15 |
| Reported EPS | -1.64 | -1.77 | -1.58 | -1.02 | -0.98 | -0.8885 | -1.03 | -1.09 | -0.9 | -0.58 | -0.74 | -1.2 |
| Estimated EPS | -1.75 | -1.48 | -1.12 | -1.0738 | -1.1036 | -1.05 | -1.11 | -1 | -0.78 | -0.8 | -0.86 | -0.68 |
| Surprise | 0.11 | -0.29 | -0.46 | 0.0538 | 0.1236 | 0.1615 | 0.08 | -0.09 | -0.12 | 0.22 | 0.12 | -0.52 |
| Surprise Percentage | 6.2857% | -19.5946% | -41.0714% | 5.0102% | 11.1997% | 15.381% | 7.2072% | -9% | -15.3846% | 27.5% | 13.9535% | -76.4706% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-07 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -1.78 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2026-03-04 23:52:34
William Savage, Chief Medical Officer of Disc Medicine Inc (IRON), sold 7,378 shares on March 2, 2026, reducing his holdings to 85,211 shares. This transaction is part of a trend over the last year where Savage has sold a total of 35,500 shares, with no insider purchases recorded for IRON during the same period. Shares were trading at $65.88 at the time of sale, giving the company a market capitalization of $2.306 billion.
2026-03-04 23:13:33
William Jacob Savage, an insider at Disc Medicine (NASDAQ:IRON), sold 7,378 shares of the company's stock on March 2nd at an average price of $65.88, totaling $486,062.64. This transaction reduced his position by 7.97%, and he now holds 85,211 shares valued at over $5.6 million. Following the news, Disc Medicine's stock traded down 5.1% to $61.10, although analysts maintain a "Moderate Buy" consensus rating with an average price target of $104.80 despite recent reductions in price objectives from several firms.
2026-03-03 20:52:22
Pomerantz LLP is investigating potential securities fraud claims against Disc Medicine, Inc. (NASDAQ: IRON) after a drug under development by the company faced a delay in its review timeline due to safety and efficacy concerns raised by U.S. Food and Drug Administration scientists. This news led to a significant drop in Disc Medicine's stock price, prompting the law firm to investigate on behalf of investors. Pomerantz LLP specializes in corporate, securities, and antitrust class action litigation.
2026-03-03 15:52:22
Disc Medicine, Inc. (IRON) is progressing with three clinical-stage programs, expecting key data readouts by the end of the year. Their lead EPP program is anticipated for launch mid-next year, contingent on Phase III results and regulatory approval, backed by strong financial health and capital efficiency. This information is derived from the TD Cowen 46th Annual Health Care Conference Audio Transcript on March 3, 2026.
2026-03-02 21:51:48
A recent Form 144 SEC filing by IRON (Disc Medicine, Inc.) details proposed and completed insider sales of common stock. The filing includes a 13,093-share sale on 12/15/2025 for $1,194,372.26 and a 3,256-share sale on 02/17/2026 for $204,672.16, both identified as 10b5-1 sales. It also notes a restricted stock unit entry for 7,378 units dated 02/15/2026.
2026-03-02 16:51:48
Wells Fargo & Company has increased its price target for Disc Medicine (NASDAQ:IRON) from $78.00 to $79.00, maintaining an "overweight" rating. This new target suggests a potential upside of 19.65% from the stock's current price. Despite significant insider selling over the past three months, the company recently reported a quarterly EPS that slightly exceeded estimates.
